HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Social Bookmarking                What's this?

Blood Glucose and Risk of Cardiovascular Disease in the Asia Pacific Region

From the Asia Pacific Cohort Studies Collaboration, Clinical Trials Research Unit, the University of Auckland, Auckland, New Zealand

Address correspondence and reprint requests to Anthony Rodgers, Asia Pacific Cohort Studies Collaboration, Clinical Trials Research Unit, the University of Auckland, Private Bag 92019, Auckland, New Zealand. E-mail: a.rodgers{at}ctru.auckland.ac.nz

OBJECTIVE—To assess the shape and strength of the association between usual blood glucose and cardiovascular disease (CVD) in Asian and Australasian cohorts and to determine the impact of adjusting for other determinants of CVD risk and excluding people with diabetes.

RESEARCH DESIGN AND METHODS—Relative risk estimates and 95% CIs were calculated from Cox models, stratified by sex and cohort, and adjusted for age at risk on individual participant data from 17 cohort studies. Repeat measurements of blood glucose were used to adjust for regression dilution bias.

RESULTS—Fasting blood glucose data were available for 237,468 participants, and during 1.2 million person-years of follow-up, there were 1,661 stroke and 816 ischemic heart disease (IHD) events. Data were also available on 27,996 participants with nonfasting glucose measurements. Continuous positive associations were demonstrated between usual fasting glucose and the risks of CVD down to at least 4.9 mmol/l. Overall, each 1 mmol/l lower usual fasting glucose was associated with a 21% (95% CI 18–24%) lower risk of total stroke and a 23% (19–27%) lower risk of total IHD. The associations were similar in men and women, across age-groups, and in Asian compared with Australasian (Australia and New Zealand) populations. Adjusting for potential confounders or removing those with diabetes as baseline did not substantially affect the associations. Associations for nonfasting glucose were weaker than those with fasting glucose.

CONCLUSIONS—Fasting blood glucose is an important determinant of CVD burden, with considerable potential benefit of usual blood glucose lowering down to levels of at least 4.9 mmol/l.

Abbreviations: APCSC, Asia Pacific Cohort Studies Collaboration • CVD, cardiovascular disease • IHD, ischemic heart disease • OGTT, oral glucose tolerance test

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. C. Gerstein, K. Swedberg, J. Carlsson, J. J. V. McMurray, E. L. Michelson, B. Olofsson, M. A. Pfeffer, S. Yusuf, and for the CHARM Program Investigators The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program Arch Intern Med, August 11, 2008; 168(15): 1699 - 1704. [Abstract] [Full Text] [PDF]

				N. Bouatia-Naji, G. Rocheleau, L. Van Lommel, K. Lemaire, F. Schuit, C. Cavalcanti-Proenca, M. Marchand, A.-L. Hartikainen, U. Sovio, F. De Graeve, et al. A Polymorphism Within the G6PC2 Gene Is Associated with Fasting Plasma Glucose Levels Science, May 23, 2008; 320(5879): 1085 - 1088. [Abstract] [Full Text] [PDF]

				The DREAM Trial Investigators Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial Diabetes Care, May 1, 2008; 31(5): 1007 - 1014. [Abstract] [Full Text] [PDF]

				P. E Norman, L. Flicker, O. P Almeida, G. J Hankey, Z. Hyde, and K. Jamrozik Cohort Profile: The Health In Men Study (HIMS) Int. J. Epidemiol., March 3, 2008; (2008) dyn041v1. [Full Text] [PDF]

				C. Bianchi, R. Miccoli, G. Penno, and S. Del Prato Primary Prevention of Cardiovascular Disease in People With Dysglycemia Diabetes Care, February 1, 2008; 31(Supplement_2): S208 - S214. [Abstract] [Full Text] [PDF]

				R. S. Vasan What is an Abnormal Blood Glucose Level?: Combining Lessons From Epidemiology and In Vivo Plaque Imaging J. Am. Coll. Cardiol. Img., January 1, 2008; 1(1): 46 - 48. [Full Text] [PDF]

				M. Janghorbani, F. B. Hu, W. C. Willett, T. Y. Li, J. E. Manson, G. Logroscino, and K. M. Rexrode Prospective Study of Type 1 and Type 2 Diabetes and Risk of Stroke Subtypes: The Nurses' Health Study Diabetes Care, July 1, 2007; 30(7): 1730 - 1735. [Abstract] [Full Text] [PDF]

				G. Hu, P. Jousilahti, S. Bidel, R. Antikainen, and J. Tuomilehto Type 2 Diabetes and the Risk of Parkinson's Disease Diabetes Care, April 1, 2007; 30(4): 842 - 847. [Abstract] [Full Text] [PDF]

				C. Held, H.C. Gerstein, S. Yusuf, F. Zhao, L. Hilbrich, C. Anderson, P. Sleight, K. Teo, and for the ONTARGET/TRANSCEND Investigators Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk Circulation, March 20, 2007; 115(11): 1371 - 1375. [Abstract] [Full Text] [PDF]

				H. C. Gerstein Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach Diabetes Care, February 1, 2007; 30(2): 432 - 434. [Full Text] [PDF]

				A. Ansary-Moghaddam, R. Huxley, F. Barzi, C. Lawes, T. Ohkubo, X. Fang, S. H. Jee, M. Woodward, and Asia Pacific Cohort Studies Collaboration The Effect of Modifiable Risk Factors on Pancreatic Cancer Mortality in Populations of the Asia-Pacific Region Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2435 - 2440. [Abstract] [Full Text] [PDF]

				M Woodward, F Barzi, A Martiniuk, X Fang, D. Gu, Y Imai, T. Lam, W. Pan, A Rodgers, I Suh, et al. Cohort profile: the Asia Pacific Cohort Studies Collaboration Int. J. Epidemiol., December 1, 2006; 35(6): 1412 - 1416. [Full Text] [PDF]

				G. J. Hankey Potential New Risk Factors for Ischemic Stroke: What Is Their Potential? Stroke, August 1, 2006; 37(8): 2181 - 2188. [Abstract] [Full Text] [PDF]

				S. H. Kim, L. Chunawala, R. Linde, and G. M. Reaven Comparison of the 1997 and 2003 American Diabetes Association Classification of Impaired Fasting Glucose: Impact on Prevalence of Impaired Fasting Glucose, Coronary Heart Disease Risk Factors, and Coronary Heart Disease in a Community-Based Medical Practice J. Am. Coll. Cardiol., July 18, 2006; 48(2): 293 - 297. [Abstract] [Full Text] [PDF]

				G. Hu, C. Sarti, P. Jousilahti, M. Peltonen, Q. Qiao, R. Antikainen, and J. Tuomilehto The Impact of History of Hypertension and Type 2 Diabetes at Baseline on the Incidence of Stroke and Stroke Mortality Stroke, December 1, 2005; 36(12): 2538 - 2543. [Abstract] [Full Text] [PDF]

				C. P. Wen, T. Y. D. Cheng, S. P. Tsai, H. L. Hsu, and S. L. Wang Increased Mortality Risks of Pre-Diabetes (Impaired Fasting Glucose) in Taiwan Diabetes Care, November 1, 2005; 28(11): 2756 - 2761. [Abstract] [Full Text] [PDF]

				A. Scuteri, S. S. Najjar, D. Muller, R. Andres, C. H. Morrell, A. B. Zonderman, and E. G. Lakatta apoE4 allele and the natural history of cardiovascular risk factors Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E322 - E327. [Abstract] [Full Text] [PDF]